A FRESH plunder complaint against Executive Secretary Ralph G. Recto and former Philippine Health Insurance Corp. (PhilHealth) President Emmanuel R. Ledesma, JrA FRESH plunder complaint against Executive Secretary Ralph G. Recto and former Philippine Health Insurance Corp. (PhilHealth) President Emmanuel R. Ledesma, Jr

Fresh plunder complaint filed against Recto, Ledesma over PhilHealth fund transfer

By Erika Mae P. Sinaking

A FRESH plunder complaint against Executive Secretary Ralph G. Recto and former Philippine Health Insurance Corp. (PhilHealth) President Emmanuel R. Ledesma, Jr. was filed before the Office of the Ombudsman on Thursday over the alleged illegal transfer of P60 billion in reserve funds.

The complaint was filed by a coalition of Ilonggo doctors, lawyers, and health advocates seeking a preliminary investigation and the determination of possible criminal, civil, and administrative liability for plunder, technical malversation, violations of the Anti-Graft and Corrupt Practices Act, and grave misconduct. 

“The respondents deliberately, willfully, and maliciously, acting with evident bad faith, dishonesty, and grave misconduct, unlawfully and intentionally caused the transfer of P60 billion in PhilHealth reserve funds to the National Treasury,” the complainants said in their complaint-affidavit.

The filing centers on Department of Finance Circular No. 003-2024, which ordered the remittance of so-called “excess” funds of government-owned and -controlled corporations to bankroll unprogrammed appropriations under the 2024 General Appropriations Act. PhilHealth transferred P60 billion in three tranches before the Supreme Court (SC) issued a temporary restraining order stopping further transfers, leaving P29 billion unreleased, the complainants said.

In its ruling last year, the SC noted that Mr. Recto, who issued the transfer order as Finance secretary, acted in “institutional good faith” and performed a “strictly ministerial” role by following Congress’ instructions.

The Court, however, did not rule on whether he could be held personally liable for technical malversation or plunder, focusing instead on the legality of the budget provision itself.

Despite this, the complainants said that the transfer was illegal, arguing PhilHealth funds are meant solely for health services and member benefits — not for general government spending — and that the law clearly forbids moving these funds to the National Government.

In response to the new complaints, Mr. Recto maintained that he acted in accordance with the law and in good faith, citing the Supreme Court ruling.

“No criminal liability may attach to me, as former secretary of Finance, for acting in good faith and in accordance with a direct mandate from Congress in ordering the remittance of PhilHealth’s unused funds,” he said.

“The issue has already been addressed by the Supreme Court, and the government has fully complied with its ruling. Consistent with this, funding for PhilHealth has since been restored and even augmented to better serve our countrymen,” Mr. Recto said.

Mr. Ledesma did not immediately reply to a Viber message seeking comment.

“No portion of the reserve fund or income thereof shall accrue to the general fund of the National Government or to any of its agencies,” the complaint quoted from the Universal Health Care Act.

The group said the plunder charge is anchored on the alleged illegal diversion of public funds amounting to far more than the P50-million threshold under the Anti-Plunder Act, arguing that the transfer caused “substantial damage and serious prejudice” to PhilHealth and its members.

They also cited the high court ruling that declared the budget provision allowing the transfer invalid, saying Congress cannot alter the Universal Health Care law through a budget measure.

The complainants also claimed PhilHealth lost more than P50 million in potential interest income, which could have been used to expand health benefits or reduce member contributions.

“PhilHealth and its contributing members have lost so much which has a direct impact on the latter’s benefits,” the complaint said.

The complainants, who identified themselves as PhilHealth members and taxpayers, said the filing seeks accountability for the diversion of funds “earmarked exclusively for public health” and warned that allowing such transfers undermines the sustainability of the country’s universal health care system.

Market Opportunity
Gravity Logo
Gravity Price(G)
$0.00485
$0.00485$0.00485
+1.82%
USD
Gravity (G) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23